GBI's Green Globes & Green Globes Journey to Net Zero Certifications Provide Access to CIRRUS C-PACE Financing for Commercial Real Estate
'GBI is excited to work alongside PACE Equity to help property owners reduce their carbon footprint and increase energy efficiency,' said Vicki Worden, GBI President & CEO. 'Green Globes and Green Globes Journey to Net Zero programs demonstrate accountability and can unlock critical lower cost capital to support projects that are focused on improving the sustainability of the built environment.'
'This collaboration between PACE Equity and GBI means the developers of Green Globes and Journey to Net Zero buildings have an advantage. They can combine the benefits of building sustainably with the benefits of smart financing. Together these benefits substantially impact project returns,' said Beau Engman, president and founder of PACE Equity.
Green Globes is a science- and consensus-based comprehensive certification system that evaluates the sustainability, health, and resilience of commercial real estate. Green Globes Journey to Net Zero empowers all commercial real estate owners to evaluate current site Energy Use Intensity (EUI) and/or carbon emissions (CO2e) and implement impactful change. The assessment processes of both programs are educational and transparent throughout. Project teams are supported by best-in-class service from GBI Project Managers and Green Globes Assessors (GGA) and receive a final report that serves as a roadmap for future improvement.
To date, GBI has certified over 800 million square feet of commercial real estate, working with project teams to guide design, provide timely feedback, and assess operational performance. By including Green Globes and Green Globes Journey to Net Zero third-party certifications, PACE Equity is empowering clients with additional resources to meet their sustainability goals and improve asset value.
For more information, please visit: https://www.pace-equity.com/lowcarbon/certifications/.
About GBI
GBI is an international nonprofit organization and American National Standards Institute (ANSI) Accredited Standards Developer dedicated to reducing climate impacts by improving the built environment. Founded in 2004, the organization is the global provider of the Green Globes®, Green Globes Journey to Net Zero™ and federal Guiding Principles Compliance building assessment and certification programs. GBI also issues professional credentials, including the Green Globes Professional (GGP) and Guiding Principles Compliance Professional (GPCP). To learn more about opportunities to become involved with GBI, contact info@thegbi.org or visit the GBI website at www.thegbi.org.
About PACE Equity
PACE Equity funds Commercial Property Assessed Clean Energy (C-PACE) projects with better financing for better buildings. PACE Equity has funded C- PACE projects across the U.S. and enabled the energy efficient commercial development of over $6.3 billion, while eliminating over 1.4 million metric tons of carbon. PACE Equity offers the funding and engineering support that allow customers to intelligently meet the demands of today's consumer and tomorrow's building requirements. Visit www.pace-equity.com to get started.
MEDIA CONTACT Megan Baker, GBI Vice President of Engagement, (971) 256-7174 megan@thegbi.orgSign in to access your portfolio
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Larkspur Biosciences Announces Discovery of LRK-4189, a First-in-Class Degrader of the Lipid Kinase PIP4K2C, for the Treatment of Microsatellite Stable (MSS) Colorectal Cancer at the ACS Fall 2025 Meeting
First-in-human, Phase 1 Study of LRK-4189 to Begin in the Fourth Quarter CAMBRIDGE, Mass., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Larkspur Biosciences, a company pioneering a new wave in cancer therapy that destroys tumors by targeting cancer cell fitness, today announced the discovery of LRK-4189, a first-in-class degrader of the lipid kinase PIP4K2C for the treatment of microsatellite stable (MSS) colorectal cancer (CRC) and other solid tumors. The announcement was made at a presentation Larkspur was invited to give at the prestigious MEDI First Time Disclosures: Breakthroughs on New Medicines session at ACS Fall 2025, a meeting of the American Chemical Society in Washington, DC. Cancer cells maintain their fitness by developing survival adaptations that foster escape from intrinsic and extrinsic mechanisms of cell death in conditions of stress. Phosphatidylinositol 5-phosphate 4-kinase, type II, gamma (PIP4K2C) is a lipid kinase associated with poor outcomes in a range of cancers including CRC and breast cancers. PIP4K2C is co-opted by cancer cells to increase their fitness by evading immune surveillance and adapting to stress. 'Genetic studies have long highlighted PIP4K2C as a key player in cancer stress adaptation, but its extremely low kinase activity made it resistant to conventional inhibition approaches,' said Catherine Sabatos-Peyton, PhD, CEO of Larkspur Biosciences. 'With our novel degrader, LRK-4189, we've finally unlocked this critical pathway. By reducing cancer cell fitness, triggering intrinsic apoptosis, and engaging the immune system to clear residual tumor cells, LRK-4189 has the potential to overcome the limitations of earlier therapies. We're excited to advance this promising therapy to the clinic later this year.' According to the American Cancer Society, in the United States, approximately 150,000 cases of CRC are diagnosed annually, with MSS CRC accounting for about 85% of all CRC cases. About LRK-4189 LRK-4189 is an orally bioavailable, selective degrader of PIP4K2C with subnanomolar potency in primary human cells. LRK-4189-mediated degradation of PIP4K2C leads to intrinsic cancer cell death and activates interferon signaling, triggering multiple killing mechanisms in difficult-to-treat MSS CRC cells. In vivo, LRK-4189 demonstrates dose dependent PKPD with single agent efficacy in multiple models of CRC and synergy with first-line standard of care chemotherapy. In primary human CRC patient-derived spheroids, 50% of patient samples respond to LRK-4189 with a preferential response in MSS CRC, which compares favorably to benchmark cetuximab in the same platform (35%). Cetuximab may be either a first- or second-line treatment in people with RAS wild type CRC. LRK-4189 has completed IND-enabling studies and expects to initiate a Phase 1 clinical trial in Q4 2025. About Larkspur Biosciences Larkspur Biosciences is pioneering a new wave in cancer therapy that destroys tumors by targeting cancer cell fitness. Larkspur develops therapies that decrease cancer cell fitness and sensitizes the cells to intrinsic and immune-driven mechanisms of killing. The company is advancing first-in-class programs that target the adaptations cancer cells use to proliferate, invade tissue, and escape the immune system. LarkX, the company's proprietary bioinformatics platform, couples machine learning with tumor genetics to discover cancer cell fitness pathways that originate in the tumor and enrich clinical strategies for potential responders to its therapies across multiple types of cancer. Larkspur's founders include Lewis C. Cantley, PhD, professor of medicine at Dana-Farber Cancer Institute, professor of cell biology at Harvard Medical School; Vijay K. Kuchroo, DVM, PhD, professor of neurology at Harvard Medical School, senior scientist at Brigham and Women's Hospital; and Nathanael Gray, PhD, professor of chemical and systems biology at Stanford University. Visit us at and follow us on LinkedIn and X. Media Contact:Dan BoyleScientPRdan@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Hepsiburada Submits Amendment to 6-K
ISTANBUL, Aug. 20, 2025 (GLOBE NEWSWIRE) -- On August 15, 2025, D-MARKET Elektronik Hizmetler ve Ticaret Anonim Şirketi (the 'Company') furnished to the Securities and Exchange Commission a Form 6-K (the 'Original Form 6-K') containing certain exhibits relating to the Company's Annual General Assembly Meeting of Shareholders for, and with respect to, the financial year 2024, to be held on September 15, 2025. This Amendment No. 1 to the Original Form 6-K amends the Original Form 6-K solely for the purpose of amending and restating Exhibit 99.4 (Board of Directors' Annual Report for 2024) in its entirety, due to an inadvertent clerical error contained in the version included in the Original Form 6-K. Except as described above, the Original Form 6-K remains unchanged. About Hepsiburada Hepsiburada is a leading e-commerce technology platform in Türkiye, operating through a hybrid model that combines first-party direct sales (1P) and a third-party marketplace (3P) with approximately 100 thousand its vision of leading the digitalization of commerce, Hepsiburada serves as a reliable, innovative and purpose-driven companion in consumers' daily lives. Hepsiburada's e-commerce platform offers a broad ecosystem of capabilities for merchants and consumers including last-mile delivery, fulfilment services, advertising solutions, cross-border sales, payment services and affordability solutions. Hepsiburada's integrated fintech platform, Hepsipay, provides secure payment solutions, including digital wallets, general-purpose loans, buy now pay later (BNPL) and one-click checkout, enhancing shopping convenience for consumers across online and offline while driving higher sales conversions for its founding in 2000, Hepsiburada has been purpose-driven, leveraging its digital capabilities to empower women in the Turkish economy. In 2017, Hepsiburada launched the 'Technology Empowerment for Women Entrepreneurs' program, which has supported approximately 65 thousand female entrepreneurs across Türkiye in reaching millions of customers. Investor Relations Contactir@ Media Contactcorporatecommunications@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 hours ago
- Yahoo
New Balance's 'Comfortable' Fresh Foam Hiking Shoes Are Already $44 Off
The Arena Media Brands, LLC and respective content providers may receive compensation for some links to products and services on this website. New Balance's 'Comfortable' Fresh Foam Hiking Shoes Are Already $44 Off originally appeared on Athlon Sports. Outdoor enthusiasts, take notice. You can score a good deal right now on a pair of New Balance Fresh Foam X Hierro Hiker Shoes, which the athletic retailer describes as "an easy-wearing, waterproof hiker with grippy treads and cushioned midsole for year-round exploration." Normally $190, New Balance is offering this newer model for 23% off, now down to $146. Sizes range from US men's 7 to 16 and US women's 5 to 13, and wide sizes are also available. The available color, pictured below, is "SHIPYARD with DOCKSIDE and Sea Salt." New Balance Reviews: What Are Customers Saying? These hybrid hikers don't have a ton of buyer reviews quite yet, but the early returns are positive, with an overall rating of 4.8 stars out of 5.0. Here is what a few shoppers have said online: "Great Hiking Shoe. Very comfortable, with great support." "They fit good and look good. Have received multiple compliments wanting to know where I got them." "Very comfortable and good for long hikes on uneven terrain." Fresh Foam X Hierro Hiker Shoes, $146 (Was $190) at New Balance More Product and Shipping Details In addition to its "incredible comfort," New Balance's website highlights that the "GORE-TEX® waterproof fabric protects feet from wind, rain and water without sacrificing breathability." These also offer Toe Protect technology, which helps shield your feet from "rocks, roots and debris" as you soak in the trails. Free shipping is offered on these hiking shoes, but be sure to allow up to 2-5 business days once shipped. Store pickup is available at select locations. New Balance's 'Comfortable' Fresh Foam Hiking Shoes Are Already $44 Off first appeared on Athlon Sports on Aug 20, 2025 This story was originally reported by Athlon Sports on Aug 20, 2025, where it first appeared.
